Comparative study of biological versus synthetic prostheses in the treatment of ventral hernias classified as grade II/III by the Ventral Hernia Working Group
Copyright © 2021. Published by Elsevier Masson SAS..
AIM OF THE STUDY: The implantation of biological prostheses in an at-risk environment has seen increasing use. Their markedly higher cost compared to synthetic prostheses makes it important to analyse their usefulness in terms of actual benefit and cost-effectiveness. This study aims to examine the relevance of bioprostheses during surgical repair of Grade II/III ventral hernias as classified by the Ventral hernia working group (VHWG).
MATERIALS AND METHODS: This study analysed the data of 119 patients requiring non-emergency repair of VHWG II/III grade hernias between 2010 and 2017. The results of patients who were treated with a bioprosthesis (n=59) were compared to those receiving a synthetic prosthesis (n=60). The primary outcome was surgical site infection (SSI) at 90 days. The secondary endpoints were hernia recurrence rate, cost of the prosthesis, duration of hospital stay and re-hospitalisation rate.
RESULTS: The two groups were shown to be comparable by analysis of demographic, pre- and intraoperative data. The SSI rate was significantly higher in the bioprosthesis group (20% vs. 7%; P=0.010), as was the recurrence rate (56% vs. 28%; P=0.003) with a median follow-up of 40 months. The cost of the bioprosthesis was significantly higher than that of the synthetic prosthesis (€3363 vs. €249; P<0.010).
CONCLUSION: In this retrospective study, the use of a bioprosthesis for repair of VHWG II/III ventral hernias was associated with a higher rate of both SSI and hernia recurrence at a cost 13 times greater than the use of a synthetic prosthesis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:159 |
|---|---|
| Enthalten in: |
Journal of visceral surgery - 159(2022), 2 vom: 15. Apr., Seite 98-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herrero, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological prosthesis |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 13.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jviscsurg.2021.02.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325702500 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325702500 | ||
| 003 | DE-627 | ||
| 005 | 20231225193010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jviscsurg.2021.02.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325702500 | ||
| 035 | |a (NLM)34020911 | ||
| 035 | |a (PII)S1878-7886(21)00033-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herrero, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative study of biological versus synthetic prostheses in the treatment of ventral hernias classified as grade II/III by the Ventral Hernia Working Group |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 13.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Masson SAS. | ||
| 520 | |a AIM OF THE STUDY: The implantation of biological prostheses in an at-risk environment has seen increasing use. Their markedly higher cost compared to synthetic prostheses makes it important to analyse their usefulness in terms of actual benefit and cost-effectiveness. This study aims to examine the relevance of bioprostheses during surgical repair of Grade II/III ventral hernias as classified by the Ventral hernia working group (VHWG) | ||
| 520 | |a MATERIALS AND METHODS: This study analysed the data of 119 patients requiring non-emergency repair of VHWG II/III grade hernias between 2010 and 2017. The results of patients who were treated with a bioprosthesis (n=59) were compared to those receiving a synthetic prosthesis (n=60). The primary outcome was surgical site infection (SSI) at 90 days. The secondary endpoints were hernia recurrence rate, cost of the prosthesis, duration of hospital stay and re-hospitalisation rate | ||
| 520 | |a RESULTS: The two groups were shown to be comparable by analysis of demographic, pre- and intraoperative data. The SSI rate was significantly higher in the bioprosthesis group (20% vs. 7%; P=0.010), as was the recurrence rate (56% vs. 28%; P=0.003) with a median follow-up of 40 months. The cost of the bioprosthesis was significantly higher than that of the synthetic prosthesis (€3363 vs. €249; P<0.010) | ||
| 520 | |a CONCLUSION: In this retrospective study, the use of a bioprosthesis for repair of VHWG II/III ventral hernias was associated with a higher rate of both SSI and hernia recurrence at a cost 13 times greater than the use of a synthetic prosthesis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological prosthesis | |
| 650 | 4 | |a Grade II/III ventral hernia | |
| 650 | 4 | |a Parietal reconstruction | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a SSI | |
| 700 | 1 | |a Gonot Gaschard, M |e verfasserin |4 aut | |
| 700 | 1 | |a Bouyabrine, H |e verfasserin |4 aut | |
| 700 | 1 | |a Perrey, J |e verfasserin |4 aut | |
| 700 | 1 | |a Picot, M-C |e verfasserin |4 aut | |
| 700 | 1 | |a Guillon, F |e verfasserin |4 aut | |
| 700 | 1 | |a Fabre, J-M |e verfasserin |4 aut | |
| 700 | 1 | |a Souche, R |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of visceral surgery |d 2010 |g 159(2022), 2 vom: 15. Apr., Seite 98-107 |w (DE-627)NLM199191336 |x 1878-7886 |7 nnns |
| 773 | 1 | 8 | |g volume:159 |g year:2022 |g number:2 |g day:15 |g month:04 |g pages:98-107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jviscsurg.2021.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 159 |j 2022 |e 2 |b 15 |c 04 |h 98-107 | ||